Your browser doesn't support javascript.
loading
Quality of life and sarcopenic patients.
Beaudart, Charlotte; Bonnefoy, Marc; Gilbert, Thomas; Paillaud, Elena; Raynaud-Simon, Agathe; GuÉrin, Olivier; Jeandel, Claude; Le Sourd, Bruno; Haine, Max; Ferry, Monique; Rolland, Yves; Berrut, Gilles; Reginster, Jean-Yves; Bruyère, Olivier.
Afiliação
  • Beaudart C; WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Ageing, Division of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgique.
  • Bonnefoy M; Service de médecine gériatrique, CHU Lyon, Groupement hospitalier Sud, Pierre-Bénite, Inserm U1060, Oullins, France, Membres du Groupe Expert Nutrition en Gériatrie (GEGN) sous l'égide de la SFGG.
  • Gilbert T; Service de médecine gériatrique, CHU Lyon, Groupement Hospitalier Sud, Pierre-Bénite, HESPER EA 7425 Université de Lyon, Lyon, France.
  • Paillaud E; Service de gériatrie, Hôpital européen Georges-Pompidou, AP-HP, Paris, France, Membres du Groupe Expert Nutrition en Gériatrie (GEGN) sous l'égide de la SFGG.
  • Raynaud-Simon A; Service de médecine gériatrique, Hôpital Bichat, AP-HP, Paris, France, Membres du Groupe Expert Nutrition en Gériatrie (GEGN) sous l'égide de la SFGG.
  • GuÉrin O; Service de médecine gériatrique, CHU Nice, Nice, France, Membres du Groupe Expert Nutrition en Gériatrie (GEGN) sous l'égide de la SFGG.
  • Jeandel C; Centre de gérontologie clinique Antonin Balmes, CHU Montpellier, Montpellier, France, Membres du Groupe Expert Nutrition en Gériatrie (GEGN) sous l'égide de la SFGG.
  • Le Sourd B; CHU Clermont-Ferrand, France.
  • Haine M; Service de médecine gériatrique, Centre Hospitalier Villefranche-sur-Saône, France.
  • Ferry M; Inserm U1125-Inra/Cnam, Paris, France, Membres du Groupe Expert Nutrition en Gériatrie (GEGN) sous l'égide de la SFGG.
  • Rolland Y; Gérontopôle, CHU Toulouse, Inserm UMR 1027, Toulouse, France, Membres du Groupe Expert Nutrition en Gériatrie (GEGN) sous l'égide de la SFGG.
  • Berrut G; Service de médecine gériatrique, Hopital Bellier, CHU Nantes, Nantes, France, Membres du Groupe Expert Nutrition en Gériatrie (GEGN) sous l'égide de la SFGG.
  • Reginster JY; WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Ageing, Division of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgique, Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Ri
  • Bruyère O; WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Ageing, Division of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgique, Service de médecine gériatrique, CHU Lyon, Groupement hospitalier Sud, Pierre-Bénite, Inserm U1060, Oullins, Fr
Article em En | MEDLINE | ID: mdl-35131737
Sarcopenia is defined as a progressive and generalised loss of muscle strength, muscle mass and physical performance with advancing age. Among the multiple consequences of sarcopenia, the reduction in the quality of life associated with it can undeniably be considered as a major consequence. Quality of life is measured via generic or specific questionnaires. Current research, mainly using so-called "generic" questionnaires, has identified a reduced quality of life in patients with primary age-related sarcopenia, mainly in areas related to functional status and physical performance. A specific quality of life questionnaire could, in combination with a generic questionnaire, provide more precise data on the impact that sarcopenia has on patient's quality of life. The first quality of life questionnaire specific to sarcopenia, the SarQoL®, was developed in 2015. Psychometric validation of the SarQoL® has been carried out in several international patient populations indicating excellent internal consistency, reliability and convergent validity and sensitivity to change, as well as an absence of floor and ceiling effects. In combination with a generic questionnaire, this specific questionnaire is therefore suitable for measuring the quality of life of populations suffering from sarcopenia, both in research and in clinical practice and in the context of both observational or interventional evaluations.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article